VivoSeq
Other

Arteriovenous Fistula

0

Pipeline Programs

1

Active Trials

2

Companies Involved

Arteriovenous Fistula is an early-stage landscape with 0 programs across 2 companies. The most active players are Takeda, Cyathus Exquirere Pharmaforschungsgmbh.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

70/100

Attrition Rate

23/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

13

clinical trials

Completed7 · 54%
Unknown status2 · 15%
Terminated2 · 15%
Active, not recruiting1 · 8%
Withdrawn1 · 8%

Trial Activity

13 trials

Effects of Heparin on Arteriovenous Fistula Patency
Completed··Phase 4·NCT02493504·150 enrolled
Vitamin D and Arteriovenous Fistulae
Completed·EEmory University·N/A·NCT00912782·52 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)